Published in Eur J Immunol on September 01, 1992
Quiescent haematopoietic stem cells are activated by IFN-gamma in response to chronic infection. Nature (2010) 3.93
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Gamma interferon functions in resistance to Cryptosporidium parvum infection in severe combined immunodeficient mice. Infect Immun (1993) 1.29
Tumor rejection by disturbing tumor stroma cell interactions. J Exp Med (2001) 1.22
Regulation of hepatocyte fate by interferon-γ. Cytokine Growth Factor Rev (2011) 1.13
Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha. Proc Natl Acad Sci U S A (2007) 1.08
Modulation of gamma interferon receptor 1 by Mycobacterium tuberculosis: a potential immune response evasive mechanism. Infect Immun (2007) 1.07
IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts. PLoS Med (2008) 1.04
DNA methylation represses IFN-gamma-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells. Mol Cancer Res (2008) 1.04
Local entrapment of interferon gamma in the recovery from Shigella dysenteriae type 1 infection. Gut (1996) 1.02
Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo. J Clin Invest (1994) 1.01
Gut intraepithelial lymphocytes induce immunity against Cryptosporidium infection through a mechanism involving gamma interferon production. Infect Immun (1997) 0.99
Human intestinal epithelial cell-derived interleukin (IL)-18, along with IL-2, IL-7 and IL-15, is a potent synergistic factor for the proliferation of intraepithelial lymphocytes. Clin Exp Immunol (2004) 0.92
IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol (2013) 0.91
Expression of interferon-gamma receptors on murine oligodendrocytes and its regulation by cytokines and mitogens. Immunology (1995) 0.88
Diagnostic and therapeutic challenges in a child with complete interferon-γ receptor 1 deficiency. Pediatr Blood Cancer (2015) 0.84
Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol (2016) 0.84
Interferon induction by RNA viruses and antagonism by viral pathogens. Viruses (2014) 0.84
Antagonizing interferon-mediated immune response by porcine reproductive and respiratory syndrome virus. Biomed Res Int (2014) 0.82
Malignant germ cell tumours of the testis express interferon-gamma, but are resistant to endogenous interferon-gamma. Br J Cancer (2003) 0.79
IFN-γ-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway. J Immunol Res (2014) 0.79
Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin. Clin Exp Immunol (1993) 0.78
Interferon-γ induces immunoproteasomes and the presentation of MHC I-associated peptides on human salivary gland cells. PLoS One (2014) 0.77
Prevention of adverse events of interferon γ gene therapy by gene delivery of interferon γ-heparin-binding domain fusion protein in mice. Mol Ther Methods Clin Dev (2014) 0.76
The Contribution of the Airway Epithelial Cell to Host Defense. Mediators Inflamm (2015) 0.75
Selective activation of interferon-γ signaling by Zika virus NS5 protein. J Virol (2017) 0.75
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet (2000) 6.12
Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol (1995) 3.76
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 2.96
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci (2000) 2.49
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? Eur Heart J (2001) 2.07
Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction. J Exp Med (1994) 2.00
Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med (1994) 1.95
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood (2001) 1.79
Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart (2009) 1.71
1H, 13C, and 15N NMR backbone assignments and secondary structure of human interferon-gamma. Biochemistry (1992) 1.66
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med (2001) 1.66
Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol (1995) 1.63
Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur J Immunol (1995) 1.62
Isolation and characterization of Ni-specific T cell clones from patients with Ni-contact dermatitis. J Immunol (1985) 1.59
Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J Infect Dis (2000) 1.58
Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J Biol Chem (1994) 1.46
Establishment and characterization of a human neuroblastoma cell line. Int J Cancer (1989) 1.43
Concomitant factors of decompensation in chronic heart failure. Am J Cardiol (1996) 1.42
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res (1992) 1.39
Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol (2001) 1.39
Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. J Exp Med (1996) 1.38
Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest (1999) 1.37
Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet (1987) 1.34
Interaction between the components of the interferon gamma receptor complex. J Biol Chem (1995) 1.32
Murine monoclonal antibodies against HLA structures. Immunol Rev (1979) 1.31
Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science (1985) 1.30
IFN-gamma involvement in the severity of gram-negative infections in mice. J Immunol (1993) 1.30
Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst (1997) 1.30
Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med (1997) 1.29
Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today (1994) 1.29
The role of the macrophage as the stimulator cell in contact sensitivity. J Immunol (1977) 1.28
Baculovirus stimulates antiviral effects in mammalian cells. J Virol (1999) 1.26
Treatment with homodimeric interleukin-12 (IL-12) p40 protects mice from IL-12-dependent shock but not from tumor necrosis factor alpha-dependent shock. Infect Immun (1997) 1.25
The Jak kinases differentially associate with the alpha and beta (accessory factor) chains of the interferon gamma receptor to form a functional receptor unit capable of activating STAT transcription factors. J Biol Chem (1995) 1.24
Expression of beta 1B integrin isoform in CHO cells results in a dominant negative effect on cell adhesion and motility. J Cell Biol (1994) 1.24
A flow cytometry assay simultaneously detects independent apoptotic parameters. Cytometry (2001) 1.22
The interferon gamma (IFN-gamma) receptor: a paradigm for the multichain cytokine receptor. Cytokine Growth Factor Rev (1997) 1.20
Pathology of thymic epithelial tumors. Curr Top Pathol (1986) 1.19
Natural cell-mediated cytotoxicity against Trichomonas vaginalis in the mouse. I. Tissue, strain, age distribution, and some characteristics of the effector cells. J Immunol (1980) 1.18
Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem (1999) 1.18
Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. J Immunol (1988) 1.15
Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol (1992) 1.15
Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer (1994) 1.15
A simple, rapid and large capacity ELISA for biologically active native and recombinant human IFN gamma. J Biol Regul Homeost Agents (1988) 1.14
p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer (2000) 1.14
Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res (1999) 1.14
Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med (1990) 1.14
Human interferon-gamma receptor. Mapping of epitopes recognized by neutralizing antibodies using native and recombinant receptor proteins. J Biol Chem (1990) 1.13
Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein. Ann N Y Acad Sci (2000) 1.12
The effects of a nonimmunogenic form of murine soluble interferon-gamma receptor on the development of autoimmune diabetes in the NOD mouse. Endocrinology (1996) 1.12
Thymomas. A review of 169 cases, with particular reference to results of surgical treatment. Cancer (1986) 1.11
Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol (1985) 1.11
Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. Am J Pathol (1999) 1.10
IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol (2001) 1.10
A selective defect of IFN-gamma- but not of IFN-alpha-induced JAK/STAT pathway in a subset of U937 clones prevents the antiretroviral effect of IFN-gamma against HIV-1. J Immunol (1999) 1.10
Neutrophils in the antitumoral immune response. Chem Immunol Allergy (2003) 1.09
Carcinogenicity of dimethylnitrosamine in Swiss mice. Br J Cancer (1966) 1.09
Heterologous sera: a target for in vitro cell-mediated cytotoxicity. J Immunol (1976) 1.09
Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. J Cell Physiol (1997) 1.08
Speed limit of the insulator-metal transition in magnetite. Nat Mater (2013) 1.08
Mutant lines of guinea pig L2C leukemia. I. Deletion of Ia alloantigens is associated with a loss in immunogenicity of tumor-associated transplantation antigens. J Exp Med (1976) 1.08
Immunohistological evidences of cortical and medullary differentiation in thymoma. Virchows Arch A Pathol Anat Histopathol (1985) 1.07
Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol (1987) 1.07
Environmental signals influencing expression of the IFN-gamma receptor on human T cells control whether IFN-gamma promotes proliferation or apoptosis. J Immunol (1994) 1.06
Stoichiometry of interaction between interferon gamma and its receptor. Eur J Biochem (1992) 1.05
Quantitative ultrasonic analysis of myocardium in patients with thalassemia major and iron overload. Circulation (1993) 1.05
Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol (2007) 1.05
CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells. J Immunol (1990) 1.04
Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. J Immunol (1997) 1.04
Epidemiology of pleural mesothelioma in North-western Italy (Piedmont). Br J Ind Med (1972) 1.03
Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. J Immunol (1999) 1.03
A completely automated CAD system for mass detection in a large mammographic database. Med Phys (2006) 1.03
Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol (1990) 1.02
Immunoregulatory T-cell defects in B-cell chronic lymphocytic leukemia: cause or consequence of the disease? The contributory role of decreased availability of interleukin 2 (IL-2). Blood Cells (1987) 1.01
Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother Emphasis Tumor Immunol (1995) 1.01
A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol (1999) 1.01
The effects of a monoclonal antibody to interferon-gamma on experimental autoimmune thyroiditis (EAT): prevention of disease and decrease of EAT-specific T cells. Eur J Immunol (1993) 1.00
Mouse soluble IFN gamma receptor as IFN gamma inhibitor. Distribution, antigenicity, and activity after injection in mice. J Immunol (1993) 1.00
Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res (2000) 1.00
Interleukin-2 prevention of apoptosis in human neutrophils. Eur J Immunol (1994) 0.99
Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood (2000) 0.99
Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex. Structure (2000) 0.99